Recombinant FVIII therapy eliminates many of previous concerns with plasma-derived products, but often at a high cost which can exceed $600,000/year [16].Prophylactic infusions of FVIII lead to fewer chronic joint changes or additional major complications [17,18]. this disorder. Virtually all of these therapies have in common a rise in the plasma level of FVIII, and […]